{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:13:59Z","timestamp":1777670039387,"version":"3.51.4"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Chronic hepatitis B (HB) remains a significant global health concern, despite the widespread availability of the HB vaccine. While the standard vaccine demonstrates an impressive serological response rate exceeding 90%, a subset of individuals exhibit suboptimal immunity. This study aims to elucidate the efficacy of the AS04C-adjuvanted HB vaccine in addressing non-responsiveness.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Conducted at the Preventive Medicine Service of the University Albacete Hospital in Spain from 2017 to 2021, this single-center observational study enrolled 195 patients. Among them, 126 (65%) were classified as non-responders following one or two complete standard vaccination courses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>After the administration of a complete four-dose regimen of the AS04C-adjuvanted vaccine, 73.81% of non-responder patients exhibited antibody titers indicative of robust immunity (anti-HBs &amp;gt;10).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These findings underscore the pivotal role of the AS04C-adjuvanted HB vaccine in addressing non-responsiveness, emphasizing its potential as a crucial tool in augmenting immunization strategies for various populations. This includes non-responders to standard vaccination, individuals with chronic kidney disease, those requiring seroprotection due to factors like immunosuppression or occupational hazards, as well as patients for whom conventional revaccination strategies have proven futile. Additional research is needed to expand on the promising results obtained through our protocol.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/trstmh\/trad078","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T10:05:17Z","timestamp":1698487517000},"page":"170-177","source":"Crossref","is-referenced-by-count":2,"title":["Using the AS04C-adjuvanted hepatitis B vaccine in patients classified as non-responders"],"prefix":"10.1093","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6204-5402","authenticated-orcid":false,"given":"Sara","family":"Fern\u00e1ndez S\u00e1nchez-Escalonilla","sequence":"first","affiliation":[{"name":"Department of Preventive Medicine and Public Health, University Hospital , Toledo 45007 , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9914-2505","authenticated-orcid":false,"given":"Jesus","family":"Gonzalez-Rubio","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences. Faculty of Medicine of Albacete. University of Castilla-La Mancha. \u00a0 Albacete 02008 \u00a0 Spain"},{"name":". \u00a0 Albacete 02008 \u00a0 Spain"},{"name":"Centre for Biomedical Research (CRIB). University of Castilla-La Mancha. \u00a0 Albacete 02008 \u00a0 Spain"},{"name":". \u00a0 Albacete 02008 \u00a0 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9939-6003","authenticated-orcid":false,"given":"Alberto","family":"Najera","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences. Faculty of Medicine of Albacete. University of Castilla-La Mancha. \u00a0 Albacete 02008 \u00a0 Spain"},{"name":". \u00a0 Albacete 02008 \u00a0 Spain"},{"name":"Centre for Biomedical Research (CRIB). University of Castilla-La Mancha. \u00a0 Albacete 02008 \u00a0 Spain"},{"name":". \u00a0 Albacete 02008 \u00a0 Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Miguel","family":"Cantero Escribano","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Public Health, Albacete University Teaching Hospital Complex, Albacete 02006 , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Jes\u00fas","family":"Molina Cabrero","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Public Health, Albacete University Teaching Hospital Complex, Albacete 02006 , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Garc\u00eda Guerrero","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine and Public Health, Albacete University Teaching Hospital Complex, Albacete 02006 , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,10,28]]},"reference":[{"key":"2024030418084708800_bib1","doi-asserted-by":"crossref","first-page":"50","DOI":"10.7150\/ijms.2.50","article-title":"Epidemiology and prevention of Hepatitis B virus infection","volume":"2","author":"Hou","year":"2005","journal-title":"Int J Med Sci"},{"key":"2024030418084708800_bib2","author":"World Health Organization","year":"2023"},{"issue":"2","key":"2024030418084708800_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"As","year":"2007","journal-title":"Hepatol Baltim Md"},{"issue":"5","key":"2024030418084708800_bib4","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1006\/smvy.1993.1024","article-title":"Epidemiology of viral hepatitis: an overview","volume":"4","author":"Mast","year":"1993","journal-title":"Semin Virol"},{"issue":"Suppl 1","key":"2024030418084708800_bib5","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/0264-410X(95)93549-O","article-title":"Hepatitis B prevention in Europe: a preliminary economic evaluation","volume":"13","author":"Van Damme","year":"1995","journal-title":"Vaccine"},{"issue":"8","key":"2024030418084708800_bib6","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.cgh.2007.06.015","article-title":"Risk and predictors of mortality associated with chronic Hepatitis B infection","volume":"5","author":"Iloeje","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024030418084708800_bib7","volume-title":"Informe de Utilidad Terap\u00e9utica de las Vacunas Frente al Virus de la Hepatitis B (versi\u00f3n 2)","author":"Ministerio de Sanidad, Servicios Sociales e Igualdad","year":"2013"},{"issue":"43","key":"2024030418084708800_bib8","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.15585\/mmwr.mm7043a1","article-title":"Routine vaccination coverage\u2014Worldwide, 2020","volume":"70","author":"Muhoza","year":"2021","journal-title":"Morb Mortal Wkly Rep"},{"key":"2024030418084708800_bib9","article-title":"Cobertura de inmunizaci\u00f3n. Cobertura vacunal mundial en 2022","author":"World Health Organization","year":"2023"},{"issue":"6","key":"2024030418084708800_bib10","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/ibd.21147","article-title":"Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France","volume":"16","author":"Chevaux","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"2024030418084708800_bib11","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S1542-3565(04)00384-2","article-title":"18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children","volume":"2","author":"Yuen","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024030418084708800_bib12","first-page":"595","article-title":"Immunogenicity of the currently recommended pneumococcal vaccination schedule in patients with inflammatory bowel disease","volume":"70","author":"Van Aalst","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"2024030418084708800_bib13","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.1016\/S0016-5085(16)30762-4","article-title":"Antibody response to three-dose Hepatitis B vaccine is reduced in inflammatory bowel disease patients on anti-TNF medications","volume":"150","author":"Pratt","year":"2016","journal-title":"Gastroenterology"},{"key":"2024030418084708800_bib14","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.cgh.2009.06.027","article-title":"Reactivation of Hepatitis B with reappearance of Hepatitis B surface antigen after chemotherapy and immune suppression","volume":"7","author":"Palmore","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024030418084708800_bib15","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.cgh.2018.08.047","article-title":"Efficacy of high-dose, rapid, Hepatitis A and B vaccination schedules in patients with cirrhosis","volume":"17","author":"Wigg","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2024030418084708800_bib16","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.cgh.2018.04.033","article-title":"Incidence of Hepatitis B Virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists","volume":"16","author":"Pauly","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5717","key":"2024030418084708800_bib17","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1126\/science.1106442","article-title":"Immunity, inflammation, and allergy in the gut","volume":"307","author":"Macdonald","year":"2005","journal-title":"Science"},{"key":"2024030418084708800_bib18","volume-title":"Vacunaci\u00f3n en Grupos de Riesgo de todas las Edades y en Determinadas Situaciones. Ponencia de Programa y Registro de Vacunaciones","author":"Ministerio de Sanidad, Consumo y Bienestar Social","year":"2018"},{"key":"2024030418084708800_bib19","author":"World Health Organization","year":"2012"},{"issue":"12","key":"2024030418084708800_bib20","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat Med"},{"issue":"4","key":"2024030418084708800_bib21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","article-title":"Vaccine adjuvants: putting innate immunity to work","volume":"33","author":"Coffman","year":"2010","journal-title":"Immunity"},{"key":"2024030418084708800_bib22","article-title":"Modulating vaccine responses with innate immunity","author":"Flavell","year":"2010","journal-title":"New Generation Vaccines"},{"key":"2024030418084708800_bib23","article-title":"Adjuvants for the future","author":"Kenney","year":"2010","journal-title":"New Generation Vaccines"},{"key":"2024030418084708800_bib24","author":"European Medicines Agency","year":"2018"},{"issue":"3","key":"2024030418084708800_bib25","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.vaccine.2004.06.006","article-title":"Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04","volume":"23","author":"Boland","year":"2004","journal-title":"Vaccine"},{"issue":"2","key":"2024030418084708800_bib26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1586\/14760584.6.2.133","article-title":"New hepatitis B vaccine formulated with an improved adjuvant system","volume":"6","author":"Kundi","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"2024030418084708800_bib27","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios","year":"2005"},{"issue":"1","key":"2024030418084708800_bib28","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S1473-3099(19)30417-7","article-title":"Serological response to three alternative series of hepatitis B revaccination (Fendrix, Twinrix, and HBVaxPro-40) in healthy non responders: a multicentre, open-label, randomised, controlled, superiority trial","volume":"20","author":"Raven","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"2024030418084708800_bib29","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.vaccine.2020.12.006","article-title":"Vaccination adjuvated against hepatitis B in Spanish National Healthcare System (SNS) workers typed as non responders to conventional vaccines","volume":"39","author":"Bravo-Grande","year":"2021","journal-title":"Vaccine"},{"issue":"3","key":"2024030418084708800_bib30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/QAD.0000000000002085","article-title":"Vaccination with Fendrix of prior nonresponding patients with HIV has a high success rate","volume":"33","author":"Machiels","year":"2019","journal-title":"AIDS"},{"key":"2024030418084708800_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.vacun.2019.08.012","article-title":"Uso de la vacuna frente a hepatitis B adyuvada con AS04C en pacientes con terapia biol\u00f3gica","volume":"20","author":"Fern\u00e1ndez Prada","year":"2019","journal-title":"Vacunas"},{"issue":"3","key":"2024030418084708800_bib32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/vaccines9030279","article-title":"Fendrix\u00ae vaccine effectiveness in healthcare workers who are non-responsive to Engerix B\u00ae vaccination","volume":"9","author":"Tejada-P\u00e9rez","year":"2021","journal-title":"Vaccines"},{"issue":"3","key":"2024030418084708800_bib33","doi-asserted-by":"crossref","first-page":"391","DOI":"10.7326\/0003-4819-103-3-391","article-title":"Recommendations for protection against viral hepatitis. Recommendation of the Immunization Practices Advisory Committee. Centers for Disease Control, Department of Health and Human Services","volume":"103","author":"Centers for Disease Control","year":"1985","journal-title":"Ann Intern Med"},{"key":"2024030418084708800_bib34","first-page":"1","article-title":"Informal consultation on quadrivalent diphtheria-tetanuspertussis- hepatitis B vaccine","author":"World Health Organization","year":"1992","journal-title":"Final Rep"},{"issue":"9","key":"2024030418084708800_bib35","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/j.transproceed.2012.09.046","article-title":"Efficacy of a hepatitis B vaccination schedule with two cycles of four double doses of conventional vaccine and four doses of adjuvanted vaccine in chronic kidney disease patients evaluated for renal transplantation","volume":"44","author":"Garc\u00eda-Agudo","year":"2012","journal-title":"Transplant Proc"},{"issue":"5","key":"2024030418084708800_bib36","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1111\/j.1523-1755.2005.00689.x","article-title":"Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients","volume":"68","author":"Tong","year":"2005","journal-title":"Kidney Int"},{"issue":"1","key":"2024030418084708800_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clinre.2019.06.010","article-title":"HBV vaccination with Fendrix is effective and safe in pre-dialysis CKD population","volume":"44","author":"Fabrizi","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"2","key":"2024030418084708800_bib38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.nefro.2020.08.016","article-title":"Hepatitis B virus vaccine and chronic kidney disease. The advances","volume":"41","author":"Fabrizi","year":"2021","journal-title":"Nefrologia"},{"key":"2024030418084708800_bib39","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1080\/21645515.2015.1039758","article-title":"Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: an integrated analysis","volume":"11","author":"Van Der Meeren","year":"2015","journal-title":"Hum Vaccines Immunother"},{"key":"2024030418084708800_bib40","first-page":"332","article-title":"Inmunosenescencia: efectos de la edad sobre el sistema inmune","volume":"30","author":"Saavedra Hern\u00e1ndez","year":"2014","journal-title":"Rev Cuba Hematol Inmunol Hemoter"},{"issue":"11","key":"2024030418084708800_bib41","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.14309\/ajg.0000000000000926","article-title":"Fendrix vs Engerix-B for Primo-vaccination against Hepatitis B infection in patients with inflammatory bowel disease: a randomized clinical trial","volume":"115","author":"Chaparro","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"2024030418084708800_bib42","first-page":"105","article-title":"Use of hepatitis B AS04C adjuvanted vaccine in HIV patients","volume":"31","author":"Fern\u00e1ndez-Prada","year":"2018","journal-title":"Rev Espanola Quimioter"},{"issue":"5","key":"2024030418084708800_bib43","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.chom.2011.04.006","article-title":"Trained immunity: a memory for innate host defense","volume":"9","author":"Netea","year":"2011","journal-title":"Cell Host Microbe"},{"issue":"6","key":"2024030418084708800_bib44","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"2024030418084708800_bib45","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.14309\/ajg.0000000000000921","article-title":"Improving Hepatitis B virus vaccination responses in inflammatory bowel disease: does greater dose and greater frequency lead to greater protection?","volume":"115","author":"Banty","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2024030418084708800_bib46","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0016-5085(14)62357-X","article-title":"Mo1740 Prospective, randomized clinical trial comparing the efficacy of two vaccines against Hepatitis B virus (HBV) in inflammatory bowel disease (IBD) patients","volume":"146","author":"Chaparro","year":"2014","journal-title":"Gastroenterology"},{"issue":"7","key":"2024030418084708800_bib47","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s10620-019-05595-6","article-title":"Improved antibody response to three additional hepatitis B vaccine doses following primary vaccination failure in patients with inflammatory bowel disease","volume":"64","author":"Pratt","year":"2019","journal-title":"Dig Dis Sci"},{"issue":"25","key":"2024030418084708800_bib48","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.3748\/wjg.v27.i25.3762","article-title":"Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment","volume":"27","author":"Axiaris","year":"2021","journal-title":"World J Gastroenterol"}],"container-title":["Transactions of The Royal Society of Tropical Medicine and Hygiene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/trstmh\/article-pdf\/118\/3\/170\/56827592\/trad078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/trstmh\/article-pdf\/118\/3\/170\/56827592\/trad078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T18:10:07Z","timestamp":1709575807000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/trstmh\/article\/118\/3\/170\/7331954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,28]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,10,28]]},"published-print":{"date-parts":[[2024,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/trstmh\/trad078","relation":{},"ISSN":["0035-9203","1878-3503"],"issn-type":[{"value":"0035-9203","type":"print"},{"value":"1878-3503","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2023,10,28]]}}}